Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients.
V P Retèl
,
L M G Steuten
,
J C Mewes
,
W H van Harten
More about this publication
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Volume
17
Issue nr.
7
Pages
A640
Publication date
01-11-2014
Full text links
Publisher website (DOI)
10.1016/j.jval.2014.08.2307
Europe PubMed Central
27202291
Pubmed
27202291